Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation
- PMID: 21618574
- DOI: 10.1002/hep.24451
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation
Abstract
A multicenter analysis was conducted to evaluate the main prognostic factors driving survival after radioembolization using yttrium-90-labeled resin microspheres in patients with hepatocellular carcinoma at eight European centers. In total, 325 patients received a median activity of 1.6 GBq between September 2003 and December 2009, predominantly as whole-liver (45.2%) or right-lobe (38.5%) infusions. Typically, patients were Child-Pugh class A (82.5%), had underlying cirrhosis (78.5%), and had good Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 0-1; 87.7%), but many had multinodular disease (75.9%) invading both lobes (53.1%) and/or portal vein occlusion (13.5% branch; 9.8% main). Over half had advanced Barcelona Clinic Liver Cancer (BCLC) staging (BCLC C, 56.3%) and one-quarter had intermediate staging (BCLC B, 26.8%). The median overall survival was 12.8 months (95% confidence interval, 10.9-15.7), which varied significantly by disease stage (BCLC A, 24.4 months [95% CI, 18.6-38.1 months]; BCLC B, 16.9 months [95% CI, 12.8-22.8 months]; BCLC C, 10.0 months [95% CI, 7.7-10.9 months]). Consistent with this finding , survival varied significantly by ECOG status, hepatic function (Child-Pugh class, ascites, and baseline total bilirubin), tumor burden (number of nodules, alpha-fetoprotein), and presence of extrahepatic disease. When considered within the framework of BCLC staging, variables reflecting tumor burden and liver function provided additional prognostic information. The most significant independent prognostic factors for survival upon multivariate analysis were ECOG status, tumor burden (nodules >5), international normalized ratio >1.2, and extrahepatic disease. Common adverse events were: fatigue, nausea/vomiting, and abdominal pain. Grade 3 or higher increases in bilirubin were reported in 5.8% of patients. All-cause mortality was 0.6% and 6.8% at 30 and 90 days, respectively.
Conclusion: This analysis provides robust evidence of the survival achieved with radioembolization, including those with advanced disease and few treatment options.
Copyright © 2011 American Association for the Study of Liver Diseases.
Comment in
-
Yttrium 90 therapy for hepatocellular carcinoma: Is it any better than conventional external beam radiotherapy?Hepatology. 2012 Mar;55(3):981; author reply 981-2. doi: 10.1002/hep.25535. Hepatology. 2012. PMID: 22183954 No abstract available.
Similar articles
-
Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.Cancer Biother Radiopharm. 2015 Apr;30(3):132-8. doi: 10.1089/cbr.2014.1748. Epub 2015 Mar 11. Cancer Biother Radiopharm. 2015. PMID: 25760644
-
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.J Vasc Interv Radiol. 2014 Jul;25(7):1075-84. doi: 10.1016/j.jvir.2014.04.014. Epub 2014 May 24. J Vasc Interv Radiol. 2014. PMID: 24861664 Review.
-
Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.J Gastroenterol Hepatol. 2014 Nov;29(11):1897-904. doi: 10.1111/jgh.12621. J Gastroenterol Hepatol. 2014. PMID: 24734957
-
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23. J Hepatol. 2013. PMID: 23707371 Clinical Trial.
-
Radioembolization for hepatocellular carcinoma.J Hepatol. 2012 Feb;56(2):464-73. doi: 10.1016/j.jhep.2011.07.012. Epub 2011 Aug 2. J Hepatol. 2012. PMID: 21816126 Review.
Cited by
-
Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization.Curr Oncol. 2024 May 8;31(5):2650-2661. doi: 10.3390/curroncol31050200. Curr Oncol. 2024. PMID: 38785481 Free PMC article.
-
Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere.Cardiovasc Intervent Radiol. 2024 May 14. doi: 10.1007/s00270-024-03726-9. Online ahead of print. Cardiovasc Intervent Radiol. 2024. PMID: 38744685
-
The Apparent Diffusion Coefficient of the Paraspinal and Psoas Muscles Are of Prognostic Relevance in Patients With Hepatocellular Carcinoma Undergoing Transarterial Radioembolization.Cancer Diagn Progn. 2024 May 3;4(3):281-287. doi: 10.21873/cdp.10321. eCollection 2024 May-Jun. Cancer Diagn Progn. 2024. PMID: 38707727 Free PMC article.
-
Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy.World J Gastrointest Oncol. 2024 Mar 15;16(3):761-772. doi: 10.4251/wjgo.v16.i3.761. World J Gastrointest Oncol. 2024. PMID: 38577451 Free PMC article.
-
Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review.J Liver Cancer. 2024 Mar;24(1):33-46. doi: 10.17998/jlc.2024.02.26. Epub 2024 Mar 25. J Liver Cancer. 2024. PMID: 38523467 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical